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Background: Spinal mobility limitation is a characteristic feature in Axial Spondyloarthritis 
(AxSpA). Current clinical measurements of spinal mobility have shown low criterion-concurrent 
validity. This thesis sought to determine criterion-concurrent validity for a new, and clinically 
feasible, measurement of spinal mobility in AxSpA patients using tri-axial accelerometers. 
Methods: Two perpendicular upright reference radiographs were taken followed by three flexion 
trials. For all postures, three measurements were taken: clinical tape, followed immediately by 
synchronized radiograph and accelerometer at the end ranges of forward and bilateral flexion.  
Results: In forward bending, accelerometers (r=0.590, p=0.010) had a stronger correlation to 
radiographs than all three tape measures. In lateral bending, the Lateral Spinal Flexion (r=0.743, 
p=0.001) and Domjan tape measure (r=0.708, p=0.002) correlated stronger with radiograph than 
the accelerometer method (r=0.556, p=0.016).  
Conclusion: The accelerometer measure is superior to current tape measures of spinal mobility 
in forward bending; but is outperformed in that respect by the LSF and Domjan clinical tests. 
Further evaluation of accelerometer and tape methods in early stage spinal mobility assessment 
is warranted. 
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Chapter 1: Introduction 
1.1 General Introduction 
 Axial spondyloarthritis (AxSpA) is a term used to classify a group of chronic 
inflammatory rheumatic diseases of the spine that carry a heavy burden of disease, characterized 
by pain, stiffening of the vertebral joints and progressive loss of spinal mobility. 1 The 
predominant symptoms of AxSpA are inflammation and back pain. Radiographic sacroiliitis may 
or may not also be present. 2 Thus, AxSpA can be subdivided into radiographic AxSpA and non-
radiographic AxSpA. When definitive x-ray evidence of sacroiliitis is present, the disease is 
classified as radiographic AxSpA, more classically known as ankylosing spondylitis (AS). 
Regardless of the subgroup, AxSpA patients carry a heavy burden of disease, ultimately leading 
to severe functional limitations. 1 According to a study conducted in 2012 on the prevalence of 
Axial Spondyloarthritis in the United States, the age-adjusted prevalence of this disease was 
1.4%. 3 This corresponded to 2.7 million Americans living with AxSpA at the time of the study. 
From 1995 to 2010, the age/sex-adjusted prevalence of Radiographic AxSpA in Ontario, Canada, 
increased from 79/100,000 to 213/100,000 people and the number of new diagnoses continues to 
grow. 4 This trend of increasing prevalence is likely a result of earlier diagnoses and an increase 
in years lived with disability within the AS population. AS often goes undetected or undiagnosed 
over a prolonged period of time. For instance, it has been shown to have a diagnosis delay of five 
to ten years; this is the longest delay when considering those of all common inflammatory 
rheumatic disorders. 5 This disease typically manifests in the teenage years or early twenties but 
due to the current classification criteria, early identification is rare and subsequently, treatment 
often begins much later than optimal. Previous New York criteria used for AS mandated some 
radiographic evidence of damage in the SI joint.  Since a period of time is required for these 
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findings to become visible on radiographs, this diagnostic requirement resulted in a delay 
between the onset of symptoms to diagnosis. It is expected that the new classification criteria for 
AxSpA, established in 2009 by the Assessments of SpondyloArthritis Society (ASAS), should 
reduce the diagnosis delay in this patient population by documenting sacroiliitis via MRI or 
through HLA-B27 positivity and clinical features of SpA. 6,7 
AxSpA is typically associated with back pain, morning and evening stiffness, joint 
inflammation and proliferative bone formation. 8 Due to the early presentation of signs and 
symptoms, disease identification and management are imperative to maintaining functional 
mobility and quality of life in those affected by AxSpA. 8 Disease management in AxSpA 
focuses on symptom relief and minimizing or avoiding the structural damage responsible for 
physical and functional impairments. The sacroiliac (SI) and intervertebral joints are of primary 
focus as the manifestation and progression of the disease occurs largely in these structures. 9  
Clinical measures of spinal mobility are a standard element in the assessment of patients 
with spinal disease. In AxSpA, these measures are vital both because mobility limitations are an 
indicator of disease progression and also because there is evidence that they are a predictor of 
poor outcomes. 10 The ASAS recommends the assessment of spinal mobility for monitoring 
disease activity and for the assessment of disease-modifying treatment responses. 11 Tape 
measure methods such as the Schober’s tests of forward spine bending range as well as the 
Lateral Spinal Flexion (LSF) test are commonly used to assess mobility in the clinical follow-up 
of this population. Rezvani et al. (2012) examined the reliability and validity of these tape 
measurements to assess sagittal plane spine mobility of AS patients in a controlled clinical study. 
This study found weak correlation between tape measure methods and radiographic analysis 
(gold standard), also suggesting low validity of these measures. 12 Further, a systematic review 
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by Castro et al. (2015) concluded that the spinal mobility tests currently used in clinical practice 
such as those using a measuring tape, inclinometer or goniometer have low criterion-concurrent 
validity with poor correlation to a gold standard. 13 Therefore, these measures may not provide 
an accurate measure of spine motion and may contribute to inadequate disease management. 
Despite this shortcoming, these convenient measures are currently in routine clinical use 
worldwide. 13 Thus, there is a need for further research to explore improved clinical measures of 
spinal mobility that are valid, reliable and simple to apply.  
 This thesis will explore the use of tri-axial accelerometers as a measure of frontal and 
sagittal plane spinal mobility in AxSpA. If shown to be more valid than traditional tape 
measures, these sensors have the potential to improve current monitoring methods for spinal 
mobility in primary care and with rheumatologists who are interested in the response to biologic 
therapy. This is important, as early identification of limitations and progression can lead to 
improved clinical outcomes with earlier treatment in the AxSpA population.  
 
1.2 Objective 
The objective of this thesis was to determine the criterion-concurrent validity of spine 
mobility measurement by accelerometers and traditional tape measures compared to the 
radiographic gold standard.  
 
1.3 Hypothesis 
 It was hypothesized that tri-axial accelerometers would provide a more valid 
measurement of spinal mobility than traditional tape measures. Specifically, it was expected that 
the use of tri-axial accelerometers would have a stronger Pearson (r) correlation coefficient than 
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Chapter 2: Review of Literature 
2.1 An Overview of Axial Spondyloarthritis 
2.1.1 The History of AxSpA 
Axial Spondyloarthritis is a chronic inflammatory disease that affects the sacroiliac (SI) 
joints and the spine. AxSpA is a relatively new term that has emerged across medical literature in 
response to a series of studies conducted by the ASAS, addressing the challenges in classifying 
spondyloarthritis (SpA). 6,7 By definition, AxSpA is considered a form of spondyloarthritis 
where the predominant symptoms are inflammation and back pain where radiographic evidence 
of sacroiliitis may or may not be present. 2 This broader definition formed the foundation of the 
recent classification of radiographic and non-radiographic AxSpA subgroups, thereby resolving 
the classification issue in cases where progression of the disease are not severe enough to present 
radiographic changes. When definitive x-ray evidence of sacroiliitis is present, the disease is 
classified as radiographic AxSpA, more classically known as ankylosing spondylitis (AS). Many 
clinical cases have presented typical SpA disease factors such as inflammatory back pain (IBP), 
testing positive for the HLA-B27 gene, and family history but never develop radiographically 
confirmed sacroiliitis. This subgroup is therefore classified as non-radiographic AxSpA which 
consists of SpA associated with psoriasis (PsSpA), reactive SpA (ReSpA), SpA associated with 
inflammatory bowel disease (SpAIBD), and undifferentiated SpA (uSpA).14 Ankylosing 
spondylitis accounts for about half of all AxSpA patients and is the most studied and 
documented form of AxSpA.15 
 At this time, there is no known cure for AxSpA. Experts have drawn associations to 
genetic markers such as HLA-B27 as a tool to aid with the classification of AxSpA. 10,16 85-95% 
of Caucasians of North European ancestry with AS will test positive for HLA-B27, although 
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only 7-8% of the general population who show HLA-B27 positivity will develop this disease. 3 
Further, these prevalence statistics are also variable across ethnic groups; therefore, this 
biomarker alone is not sufficient for a definitive AxSpA diagnosis. Although there have been 
advancements in the classification criteria to date, the exact etiology of the disease remains 
unknown.  
 
2.1.2 Disease Presentation 
 AxSpA is commonly associated with back pain, inflammation of SI and spinal joints, and 
proliferative bone formation. 8 This disease typically manifests in the teenage years or early 
twenties, with clinical features at presentation being generally similar between men and women. 
17,18 AxSpA course is variable but can be progressive in nature.  The typical symptom profile of 
this disease includes morning and evening stiffness, low-back pain, and joint inflammation. 8 
Early spinal involvement originates at the SI joints progressing upwards through the lumbar, 
thoracic, and in severe cases, the cervical spine. This pattern remains constant across sex, disease 
duration, and severity. 19 
Enthesitis and syndesmophyte formation are characteristic progressions that make 
AxSpA unique amongst the inflammatory rheumatic diseases. 20 Enthesitis is the inflammation 
of the insertion site of tendons and/or ligaments into the bone. 21 Syndesmophytes occur from 
progressive bone formation resulting in bony growth within the ligaments of the intervertebral 
joints. This progressive bridging/fusion across vertebrae is central to the irreversible spinal 
mobility limitations of the disease. 22 Although it is assumed that cyclic inflammation leads to 
osteoproliferation at these joints, no direct correlation between these two elements has been 
established. 8 Spinal deformity correlates with mobility limitations in both mild and severe 
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disease cases. 23 Mobility restriction increases with increased disease severity thereby 
emphasizing importance of early diagnosis and treatment to minimize progression before severe 
limitations occur.  
The presentation of syndesmophytes on a radiograph is one of the current methods for 
evaluating the progression of structural changes in the AS population 24. These structural changes 
are directly associated with spinal mobility impairments. 23 In a study investigating the natural 
disease course prior to the introduction of disease modifying anti-rheumatic drugs (DMARDs), 
Carette et al. (1983) found that greater than half of AS patients eventually develop moderate to 
severe spinal motion impairment leading to functional limitations in day to day activities.  This 
investigation found a mean onset of symptoms of 24 years of age in their 142 patient cohort with 
a mean duration of symptoms being 38 years. 23 Although this chronic disease is progressive, a 
recent prospective study reported that within a cohort of patients with new-onset non-
radiographic AxSpA, only 26% of cases went on to develop AS upon a 15 year follow-up. 17 
 
2.1.3 Pathophysiology/Pathogenesis of AxSpA 
The biological mechanisms contributing to the manifestation and further progression of 
this disease have been subject to much research in the field of rheumatology. Ossification of the 
spinal ligaments and/or annulus fibrosus of the intervertebral disc are common developments in 
this disease. The clinical course involves “quiet” periods of relatively few symptoms and active 
inflammation “flare-up” episodes with more severe symptoms. When a characteristic flare-up 
occurs, inflammatory cells increase locally, producing chemical products from cytokines and 
other bone mediators that can degrade bone. In an attempt by the body to repair the damage, new 
scar and bone tissues are formed.25 When this inflammation subsides, the body continues its 
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repair efforts by producing calcium deposits, which spread to the ligaments and joint capsules of 
the spine. 25 This proliferative bone formation is directly associated with the mobility limitations 
affecting this population. 23 It has also been suggested that repetitive biomechanical stress of the 
entheses may contribute to enthesitis and new bone formation in SpA resulting from the innate 
immune response to repetitive stress. 26 
 Genetic research has been at the forefront in attempting to draw conclusions about the 
etiology of this disease. There have been associations made between many different genetic 
biomarkers as predictors of SpA, however their direct roles remain unknown. HLA-B27 has been 
suggested to contribute to the susceptibility of AxSpA. 27 This HLA class 1 allele is positive in 
an estimated 80-90% of established AS cases, although its presence is less common (70-75%) in 
non-radiographic AxSpA patients. 28 Only an estimated 7-8% of Caucasians of North European 
ancestry who test positive for HLA-B27 will develop AS, 3 further highlighting the ill-defined 
associations between AxSpA and this biomarker. Regardless of the poor positive predictive 
value for using genetics as a definitive tool for diagnosis, the use of certain genetic markers 
remains valuable upon drawing the clinical picture for patients with AxSpA. There are three 
proposed theories of why HLA-B27 causes spondylitis. The theory of ‘molecular mimicry’ 
suggests that a cross-reactive peptide originating from a bacterial pathogen activates T cells that 
respond to an HLA-B27 associated peptide. 29 This response causes characteristic inflammation. 
A second theory is based on the reduced folding rate of disease associated HLA-B27 molecules. 
The increased assembly time in the endoplasmic reticulum (ER) causes a build-up of misfolded 
HLA-B27 molecules, resulting in ER stress. 30 The third ‘HLA-B27 homodimers theory’ 
suggests that randomly formed HLA-B27 dimers that are formed on the surface of the cell will 
bind killer immunoglobulin receptors and subsequently cause inflammation. 30 These theories are 
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a result of ongoing research into the pathogenesis of AxSpA and with further research, will likely 
form the basis for understanding the pathway of this rheumatic disease. 
 
2.2 Impact of AxSpA on the Patient 
2.2.1 Inflammatory pain  
 Back pain in individuals with AxSpA is the subsequent result of inflammation or new 
bone formation. 31 This pain can impact the life of a patient in a number of ways. While some 
studies have focused on the psychosocial impacts of inflammatory back pain (IBP), 32 the 
literature primarily focuses on the influence of IBP on physical function. 33 In a prospective 
cohort study from Kiltz et al. (2012), similar levels of pain and physical function were reported 
by AS patients and non-radiographic AxSpA patients. 2 Differentiating between mechanical back 
pain and inflammatory back pain can pose difficulties and is clinically important in diagnosing 
suspected cases. Patients with IBP generally report morning stiffness, sudden onset back pain, 
nocturnal flare ups and buttock pain. As mentioned above, disease management focuses largely 
on minimizing symptoms, therefore aiming to reduce IBP. This is crucial in maintaining patient 
quality of life, social participation and occupational contribution. Regular mobility exercises, and 
medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and biologics are the 
primary treatment recommendations for inflammatory pain reduction in this population. 2 
 
2.2.2 Spinal Mobility Impairments  
The hallmark progression of spinal motion limitation in AxSpA is a direct result of the 
intervertebral restrictions caused by inflammation and syndesmophyte formation. 23 Axial 
Spondyloarthritis has been characterized by bony fusions within the axial skeleton. The anterior 
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and posterior longitudinal ligaments, responsible for restricting extreme ranges of vertebral 
flexion/extension, further limit these ranges of motion when increased calcification is present. 34 
This process then progresses to affect the intertransverse ligaments and the annulus fibrosus of 
the intervertebral disc, which further contributes to lateral flexion restrictions in those affected by 
this disease. The damage to the axial skeleton in this condition is, in general, irreversible unless 
surgically intervened upon. However, spinal inflammation is reversible. It is important to note 
that mobility limitations are more influenced by spinal inflammation in early stages of the 
disease, further emphasizing the importance of early treatment to tackle inflammation, maintain 
mobility, and to ensure better long-term outcomes. 35 The spinal mobility impairments affecting 
AxSpA patients typically impact activities of daily living such as dressing and hygiene. 36 
Difficulties performing these everyday tasks are not only inconvenient but have been shown to 
negatively impact the psychological and emotional wellbeing of patients. 37 
 
2.2.3 Quality of Life 
 It is well documented throughout the literature that mobility restrictions and disease-
related pain affects the quality of life in AxSpA patients. 36 Limitations on physical functioning 
and independence can influence an individual’s vocational role, societal role and activities of 
daily living, which can negatively impact their emotional well-being. Approximately 66% of 
AxSpA patients report experiencing fatigue and perceive that nocturnal pain affecting their sleep 
quality was the primary contributor. 38 Both fatigue and physical limitations are major 
restrictions impacting the employment status of these individuals. In a study investigating the 
impact of work limitations in an AS patient cohort, 50% reported experiencing work instability 
while 15% reduced and/or changed their work as a result of their condition. 39 Treatment costs, 
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compounded by absence from work, can cause serious financial strain on both the individual and 
their employer. This economic burden is augmented by the typical early presentation of this 
condition making for long periods of work instability throughout an individual’s working years. 
 Spinal deformation and postural changes have also been found to negatively impact body 
image, which has been associated with increased rates of depression and anxiety. 37 In a study 
comparing AxSpA patients to the general population, rates of depression in women was 80% 
higher in the disease cohort while depression was 50% more prevalent in male patients. 40 Other 
factors impacting rates of depression and anxiety in this population are sexual dysfunction, 
impaired relationships, and intimate dissatisfaction. For example, erectile dysfunction was found 
to effect 42% of men with AxSpA compared to 18% of the general population. 41 Although 
AxSpA can have a serious impact on an individual, one can maintain a good quality of life with 
the appropriate treatment plan.  
 
2.3 Clinical Assessment of AxSpA 
2.3.1 Diagnosing AxSpA 
Symptoms that are common in this disease are often confused with mechanical or non-
inflammatory low back pain. 42 This is a problem as many cases can easily be missed or 
misdiagnosed as a different condition. For example, when a patient reports widespread peripheral 
pain concurrently with back pain, the case could become difficult to differentiate from 
fibromyalgia. 43 The progressive nature of this rheumatic disease makes early and accurate 
diagnosis critical. However, the delayed onset of AxSpA specific symptoms makes this very 
difficult. There are many factors that contribute to the inherent diagnosis delay in AxSpA. For 
decades, patients who presented with the characteristic symptoms of this condition but did not 
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demonstrate radiographic sacroiliitis would go undiagnosed. The recent changes in nomenclature 
and classification criteria, discussed above, have been a pivotal step towards tackling the 
diagnosis delay problem in this population. The difficulty in distinguishing between 
inflammatory and mechanical low back pain also presents the issue of patients being 
misdiagnosed as having chronic LBP or other arthritis conditions resulting in patients seeking 
ineffective therapies. 44 Further, a study that estimated the prevalence of clinically diagnosed AS 
in primary and secondary care simultaneously, only one-third of patients were managed at the 
secondary care level. 45 This is a problem as it indicates the majority of diagnosed patients may 
not be benefiting from additional specialist assessment. 
  The diagnosis of AxSpA is made when specific classification criteria are met. 
Distinguishing the presence of sacroiliitis on a radiograph can be difficult causing uncertainty in 
diagnosing the disease. Generating a clinical diagnosis often involves expert opinion and 
interpretation from experienced clinicians. As highlighted in Table 1, there is no definitive test to 
confirm the diagnosis. The classification criteria are based on imaging, clinical and laboratory 
data. Sacroiliitis as demonstrated on radiographic imaging is a requirement for the diagnosis of 
ankylosing spondylitis. According to the ASAS, a triad of classification criteria, which includes a 












Sacroiliitis on imaging plus  
one the following; 
HLA-B27 positive plus two 
of the following; 
Dactylitis 
Psoriasis 
Inflammatory back pain 
Good response to NSAIDs 
Arthritis 
Elevated C reactive protein 
Inflammatory bowel disease 
HLA B27 positive 
Family history of spondyloarthropathy 
Uveitis 
 
Although research continues to investigate and develop more definitive classification criteria, 
little progress has been made. This emphasizes not only the need to continue this research, but to 
also improve current clinical measures to optimize disease identification and management. 
 
2.3.2 Importance of Early Diagnosis 
 For decades, classification criteria mandating SI joint damage in the form of erosions or 
new bone formation has created a barrier to early diagnosis, and consequently the appropriate 
management, for those suffering from this disease. With radiographic sacroiliitis being a 
requirement for AS diagnosis in the past, many patients went undiagnosed for long periods of 
time because of the late onset of radiographic changes in the disease course. In other words, 
previous criteria focused the diagnosis on an advanced stage of the disease progression where 
structural damage is often irreversible. Early diagnosis in AxSpA is paramount and there is 
evidence for substantial benefit when diagnosed at an early stage. 46 Many studies have found 
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that reports of pain severity and disability in the early non-radiographic phase are comparable to 
those with radiographically confirmed disease activity. 31,47 From a clinical scope, this typical 
diagnostic delay causes patients to miss a critical window for timely and appropriate treatment. 
Aggarwal and Malavija (2009) concluded that there were statistically significant findings of 
increased disease severity, functional loss and tissue damage as a result of the typical diagnosis 
delay in AS. 5 This is important for patients as an early and accurate diagnosis can minimize 
mobility limitations and pain, while maximizing quality of life. Early diagnosis can also reduce 
the number of unnecessary diagnostic procedures or inappropriate treatments a patient may 
experience. Evidence has shown that problems deciphering between inflammatory back pain and 
mechanical back pain at the primary care level has led to diagnosis delay. 48 Practitioner 
awareness of inflammatory back pain is therefore critical to early diagnosis. Fortunately, studies 
have suggested that diagnosis delays are decreasing. 49,50 This is likely due to increased referrals 
to rheumatology, adoption of less stringent classification criteria (ASAS), and the recent 
introduction of MRI to assess SI joint inflammation. 50 With recent advancements in effective 
therapies, early diagnosis is arguably more important than ever, where proper treatment at early 
stages can significantly improve outcomes.  
  
2.3.3 Plain Film Radiography  
Plain film radiography can be used as a means to identify sacroiliitis. 51 This is the 
primary role of radiography in diagnosis and management of AS patients. These radiological 
changes present themselves much later in the disease course than initial symptoms such as low 
back pain. This is because the erosions or new bone formation can take up to 10 years to be 
visible on an x-ray film,5 which contributes to the delay in diagnosing radiographic AxSpA. In 
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AxSpA, radiographic measurement is widely considered to be the gold standard of reference in 
measuring spinal ranges of motion. 12,52,53 However, spine motion is not typically measured in 
this way because of feasibility and exposure to ionizing radiation. Using x-ray films, one can 
identify vertebral bodies and then determine the relative angle between segments of interest. This 
method can be completed directly on the developed film using a ruler and protractor or digitally 
using DICOM imaging processing software. Radiographic measurement of lumbar spine 
mobility is illustrated in Figures 5 and 6 on page 34. The increased risk inherent to ionizing 
radiation exposure poses both ethical and feasibility issues in using this method at follow up 
assessments. Radiosensitive regions such as the breast, gonads and thyroid are more sensitive to 
radiation exposure than other tissues; thus, these areas are shielded with lead during radiographic 
examinations wherever possible. Similarly, following the ALARA principle (As Low As 
Reasonably Achievable) by optimizing technique factors to use only the minimum amount of 
energy necessary as well as narrowing the field exposed through collimation are all strategies 
used to minimize the risk of this exposure. However, it is recognized that even when adhering to 
ALARA principle, the risks due to radiation exposure are never eliminated; therefore, surrogate 
measures such as the tape measure of spinal mobility are typically used. 13 
Previously, an x-ray that was graded as normal would exclude the diagnosis of AS, often 
leaving individuals undiagnosed for long periods of time or in extreme cases, never being 
diagnosed. As mentioned earlier, the recent expansion of the ASAS criteria has brought light to 
this situation by establishing the non-radiographic subgroup of axial spondyloarthritis. It is worth 
noting that individuals who are classified in the non-radiographic subgroup may progress into the 
radiographically confirmed disease group. In a review by Boonen et al. (2015), it was estimated 
that over two years, approximately 10% of non-radiographic patients progress to have 
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radiographic evidence of the disease, leading to a new diagnosis of ankylosing spondylitis. 54 
Another study completed a long-term follow up of 10 years, where they also confirmed that the 
75% of patients did not develop radiographic change. 55 
 
2.3.4 Clinical Tape Measurements 
Considering the risk of radiation exposure inherent to successive radiographic imaging, 
non-invasive methods of lumbar spine mobility measurement are used in clinical follow-ups with 
the use of standardized tape measures. Since the progressive spinal involvement of this disease 
results in limitations of spine motion, these measures can be safely taken at periodic follow-up 
appointments. The Original Schobers test (OST), Modified Schobers test (MST) and Lateral 
Spinal Flexion (LSF) test (sometimes referred to as lateral lumbar flexion test) are among the 
most frequently used tape measurements in this clinical population. 12 Both the OST and MST 
measure the sagittal plane flexion range of motion while the LSF test measures lateral spinal 
mobility in the frontal plane. 56 The OST is conducted by drawing horizontal reference lines at 
the level of the lumbosacral joint (LSJ) and 10 cm above the LSJ. With the subject in standing, 
they are instructed to bend forward at the waist as far as they can where the distance between the 
lines is re-measured. 12 The MST is conducted by drawing reference lines 5 cm below the LSJ 
and 10 cm above the LSJ followed by re-measuring the distance between the lines with the 
subject in maximum forward flexion. 12 A third variation of this test called the Modified-
Modified Schober’s test (MMST) is conducted by drawing reference lines at the level of the LSJ 
and 15 cm above the LSJ followed by re-measuring the distance between the lines with the 
subject in maximum forward flexion. 12 These three forward mobility tape measurements are 
illustrated in Figure 1 on page 19.  Other assessments include measures of chest expansion 
(sternocostal/costovertebral joint mobility), occiput-to-wall distance (cervical mobility), tragus-
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to-wall distance (cervical/thoracic mobility), and intermalleolar distance (hip mobility). 57 
However, these secondary clinical measures are unlikely to be affected without decreased spinal 
flexion measures in the frontal and sagittal planes; commonly impaired by the predominant 
involvement of the lumbosacral region. 53 These traditional tape measures are inexpensive, 
noninvasive and easy to use rendering the method an attractive alternative to radiographic 
measures of spine motion; otherwise considered the gold standard. 13  
The effectiveness of tape measurements of spinal mobility in the sagittal plane has been 
evaluated in numerous studies, which have raised questions regarding their validity. 12,53,56,58 
Rezvani et al. (2012) found a weak correlation in both the OST and MST with reference to the 
radiographic measure, yielding Pearson (r) correlation coefficients of 0.363 and 0.333, 
respectively. The MMST was also conducted in their study with researchers concluding that this 
measure did not reflect spinal mobility. Similarly, a recent systematic review by Castro et al. 
(2015) concluded that there is a lack of evidence for the criterion-concurrent validity of these 
tape measures suggesting that they are not an adequate representation of spinal motion. 13 The 
rationale as to why this measurement method lacks validity has been addressed in the literature. 
Rezvani et al. found that there was a larger systematic difference at the end ranges of spinal 
flexion when using the OST. Specifically, as the radiographic angular change increases towards 
the end ranges of forward bending, the metric changes of the OST do not increase proportionally. 
12 Miller et al. suggest that this discrepancy is potentially explained by the relationship of skin 
distraction to movement of underlying tissues. 58 With application to the AxSpA population, 
those with greater ranges of motion, who may be in early stages of the disease, will have OST 
results that will plateau before they reach a true end range of spinal flexion. In follow up 
appointments, this measure may seem to have not changed when in fact the previously taken 
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measure was not an accurate reflection of spinal mobility due to the plateau. This can give a false 
sense of successful symptom management. The lack of criterion-concurrent validity for tape 
measurement methods presents the need to explore alternative spinal mobility measures.  
The LSF measure is the recommended tape measurement for the assessment of lateral 
spinal mobility by the ASAS. This is conducted with the subject in a standing position with their 
hands at their sides. With their hand on the lateral aspect of the leg, the distance between their 
middle finger and the floor is measured in upright standing as well as ipsilateral side bending. 
The difference between upright standing and maximum lateral flexion is recorded. This is 
conducted on both sides of the body and an average of the two is taken 59 (Figure 2A). A second, 
more recently adopted measure of lateral spine bending range is the Domjan tape measurement. 
This is conducted with the participant in standing with their hands by their sides and feet 
shoulder width apart. The subject is instructed to bend maximally at the waist to the right side, 
where a horizontal mark is made on the right leg at the level of the ipsilateral middle finger. A 
second line is drawn during left lateral flexion where the tip of the middle finger of the right 
hand touches the right thigh. The distance between these two points on the right leg indicates the 
total range of lateral flexion as a combination of both sides 60 (Figure 2B). The LSF is one of the 
five widely used tape measure assessments of overall spinal mobility that make up the Bath 
Ankylosing Spondylitis Metrology Index (BASMI). Although this measure is recommended and 
used clinically, 59 there is no evidence for the criterion-concurrent validity of the LSF lateral 
measure compared to the radiographic gold standard. The same applies to the Domjan tape 
measure test of lateral spinal mobility thereby warranting the investigation of the criterion 
validity of both of these clinical tests. Collecting two tape measures of lateral bending (Domjan 




Figure 1. The three forward bending clinical tape measurements. In each panel, the left schematic 
illustrates the reference lines in upright standing while the right schematic shows the participant in 
maximal forward bending where the distance between the lines is remeasured. A. Original Schober’s 











Figure 2. The two lateral bending clinical tape measurements. A. The distance between the middle 
fingertip and the floor is recorded for upright standing and max lateral bending and the difference is 
recorded to the nearest mm. This is conducted on both sides of the body and an average of both sides 
indicates the LSF test. B. With the subject in maximal right lateral bending, a reference line is drawn at 
the level of the middle finger on the lateral aspect of the right leg. With the subject’s hands still on the 
thigh, they then maximally bend to the left side where another line is draw at the level of the middle finger 
on the right leg. The difference between these two marks on the leg is recorded to the nearest mm 
indicating the Domjan measure. Figure drawn by JC Snow. 
 
2.3.5 Tri-axial Accelerometers 
The use of accelerometers, sensors that measure acceleration, are prominent in our day-
to-day lives. They feature in both industrial and scientific applications together with gyroscopes 
and are used extensively in everything from our personal devices (phones, laptops, wearable 
fitness gear) to complex machines such as in vehicle and aircraft navigation systems. 
Accelerometers have seen a multitude of application in the fields of biomechanics, activity and 
postural analysis, gait analysis as well as in the assessment of force and impact in concussion 
research. 53-56 Three studies, conducted between 2010 and 2014, concluded that tri-axial 
accelerometers offer a valid method of trunk and center of mass acceleration during human gait. 
61–63 Since the internal validity of these sensors with reference to a camera motion capture system 
has been established in the biomechanical analysis of joint angle measurement during human 
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gait; the potential for expanded application of these sensors is compelling. Further investigation 
of biomechanical trunk measurement specifically, is of primary interest to this thesis project. 
 Tri-axial accelerometers provide output in raw data format as voltage in response to a 
change in acceleration. 64 Upon calibrating these sensors with respect to gravity (see Appendix 
A), one can then use a conversion factor from calibration trials to acquire a measure of 
acceleration from a voltage output of a given trial. Then using trigonometric functions, absolute 
angles of each accelerometer can be extracted from the accelerations present in each axis; thus 
calculating the inclination of the sensor. Using the absolute inclinations of two sensors, the 
relative angle between can then be calculated by subtraction giving a measure of spine 
kinematics. This method of measuring spine angles is very similar to how spine angles are 
calculated from radiographs (Figures 5 and 6, page 34). Theoretically, this method of spine angle 
measurement should be correlated with radiographic measures of spine angle making it a valid 
method of determining spine mobility. The technique of measuring orientations and angles using 
accelerations from a gravitational field provides great potential for expansion of accelerometer 
application in the fields of clinical biomechanics and rheumatology. 
 
2.3.6 Accelerometry for Spine Motion Measurement 
 Various techniques have been previously investigated to measure lumbar spine motion 
for clinical assessment and/or diagnosis. Many of these have been shown to have limitations or 
prove to be less than ideal. Radiographic methods are very accurate but are inherently complex 
and present health risk due to radiation exposure. Optical motion tracking equipment is 
expensive and time consuming to employ. Clinical tape measures have been proven to have very 
low criterion validity in measuring spine motion. 12 Consequently, numerous accelerometry 
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methods have been studied as a way of measuring spinal mobility. One study investigated the use 
of gyroscopes as an inertial tracking system to measure movements of the lumbar spine. 65 They 
found that in 19 healthy people, this method of measuring anatomical angles using angular rates 
of rotation in a three-dimensional coordinate system was a reliable technique in measuring 
movements of the lumbar spine. The coefficient of multiple correlation in flexion, extension and 
side bending ranged from 0.972 to 0.991 in three repeated measurements. In another study 
completed by Wong & Wong (2008), spine posture changes in sitting was compared between tri-
axial accelerometers and a 3D motion analysis system. In a small sample of three healthy 
subjects, the accelerometers were shown to fall within the accepted 5° difference in all four 
postures (neutral, forward bending, left and right lateral bending) when compared to the motion 
analysis system. 66 The results of this study verified the feasibility of using accelerometry to 
detect posture change in seated positions, while reaffirming the potential for using tri-axial 
accelerometers in the clinical measurement of spinal range of motion. For this thesis study, we 
were primarily interested in evaluating tri-axial accelerometry compared to current clinical tests 
in measuring of spinal mobility in the AxSpA population. No study has investigated the true 
criterion-concurrent validity of tri-axial accelerometers compared to the radiographic gold 
standard of spinal mobility measurement. The findings from the previous studies above 
contribute to the rationale for conducting this validation study and drive the hypothesis that 
accelerometers will correlate stronger than the clinical tape measures when compared to the 




2.4 Clinical Treatment and Management of AxSpA 
2.4.1 Patient Management/ Treatment Recommendations 
The management of AxSpA is similar between radiographic and non-radiographic 
subgroups. This is important as those who do not present radiographically confirmed AxSpA, 
still receive appropriate therapy. Treatment goals are largely focused on reducing symptoms as 
early as possible to maintain spinal mobility, reduce functional limitation, and maintain patient 
quality of life. 11 Optimal disease management combines two modalities: patient controlled 
lifestyle factors and pharmacological therapies. The goal of treatment such as pain reduction or 
increasing mobility should be established though communication between the patient and 
rheumatologist. Low impact mobility exercises as well as physical therapy are usually 
recommended by rheumatologists and have proven to be beneficial in reducing disease activity 
and improving functional status. Group physical therapy participation comprising of active, 
passive and relaxation therapies were found to be better than home-based exercises in terms of 
physical function and mobility outcomes. 67 Occupationally, individuals are recommended to 
alternate between sitting and standing to avoid exposure to prolonged postures, which may 
exacerbate stiffness and pain in the affected areas. 11 Changing other lifestyle factors such as 
smoking or drinking habits has been shown to improve outcomes. 68 Smoking is a known cause 
of inflammation and will therefore further contribute to the inflammatory pain inherent to 
AxSpA. 69 Eating habits can have either a positive or negative impact on the individual. Due to 
the association of SpA and osteoporosis, it is important to maintain a healthy diet rich in calcium. 
16 The use of pharmacological therapy concurrently with the standard non-pharmacological 
recommendations above provide great potential for optimal quality of life in this population. 11 
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2.4.2 Pharmacological therapies  
According to the Assessments of SpondyloArthritis Society (ASAS) guidelines, non-
steroidal anti-inflammatory drugs are the primary drug treatment as they have been proven to 
reduce both the pain and inflammation inherent to the disease. 70 Some studies have suggested 
that regular use of NSAIDs have a beneficial effect on structural damage of the axial skeleton. 71 
Response to this line of treatment must be monitored closely because contraindications in the 
gastrointestinal (GI) tract and/or kidneys may occur in some cases. 72 If this is the case and pain 
remains severe, other opioid-like drugs may be warranted. 11 Also used in the management of 
AxSpA is the family of disease-modifying antirheumatic drugs (DMARDs), particularly among 
patients with concomitant peripheral arthritis. In a systematic review by Zochling et al. (2006) 
investigating the effects of different drug treatments in AS patients, the use of the traditional 
DMARD, Sulfasalazine, was found to show significantly improved morning stiffness but was 
unable to improve back pain and physical function. 73 This review also highlighted that common 
adverse effects of these agents included GI and hepatic manifestations such as enzyme 
imbalances due to toxicity of the drug. 73 In the same review, the utility of Tumor Necrosis 
Alpha (TNF) inhibitors was documented. They highlighted evidence for therapeutic benefit 
with TNF inhibitors, Infliximab and Etanercept, producing significant reductions in spinal pain 
and improved physical function. 73 The benefits of these TNF inhibitors were considered rapid 
with a long therapeutic effect although treatment must be monitored to ensure a response to the 
drug. 68 Recently, the routine use of the anti interleukin-17A monoclonal antibody, 
Secukinumab, has been found to be a viable alternative to TNF inhibitors in AS patients who 
are resistant to NSAID therapy. 74 In the randomized control trial conducted by Baeten et al. 
(2013), the efficacy and safety of Secukinumab was investigated in a cohort of 30 patients with 
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moderate-to-severe AS. This research concluded that treatment with Secukinumab induced a 
clinically significant reduction of disease activity in active AS patients with significant 
improvements as early as six weeks post initiation of treatment. 74 
 
2.4.3 Monitoring Disease Progression  
The response to the treatments prescribed to AxSpA patients is central to monitoring of 
disease progression. The frequency of follow up appointments is determined on a case-by-case 
basis considering symptoms, severity and response to treatment. 11 Disease monitoring should 
also focus on patient characteristics such as functionality, disease activity and pain as reported by 
questionnaires, clinical parameters, laboratory tests and imaging. 11 Non-invasive assessments 
such as the Bath Ankylosing Spondylitis Functionality and Disease Activity Indices (BASFI and 
BASDAI) compose a series of patient reported measures that are used in monitoring 
progressions in follow up assessments. The Bath Ankylosing Spondylitis Metrology Index 
(BASMI) is composed of five measures used to assess spinal mobility in patients with AxSpA. 
Assessing spinal mobility is an accepted method of progression monitoring, where improvements 
from treatment response correlate to decreased inflammation and pain response, while increasing 
spinal ranges of motion. These measures are followed over time. 75 C-reactive proteins (CRP) are 
biomarkers in the blood that elevate in response to inflammation. Laboratory testing for CRP 
levels can provide information on patient responses to anti-inflammatory drugs upon clinical 
follow up. Radiographs are used to assess progression of fusion and/or new bone formation. 
Frequency of radiographic assessment is made on a case-by-case basis according to patient 
outcomes. 59 Similarly, medication dosing is monitored and modified according to response to 
the drug. If response to treatment brings about sustained remission, tapering of biologic 
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DMARDs should be considered. 11 The physician, usually a rheumatologist, will consider the 




This chronic form of inflammatory axial disease predominantly affects the spine and 
sacroiliac joints causing pain, stiffening of joints, and mobility limitations. These symptoms 
ultimately lead to functional impairment often causing limitations in the lives of AxSpA patients. 
The measurement of spinal mobility is clinically used as an indicator of disease progression and 
treatment response in this patient population. The literature presents evidence that does not 
support the criterion-concurrent validity of current tape measurement methods of spinal mobility. 
The identification of symptoms in this population is crucial to the clinical management of 
AxSpA patients. This population will benefit from a more valid measure of spinal mobility 
where, early identification of signs and symptoms will provide the framework for timely and 
appropriate therapy for optimal disease management in AxSpA.  
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Chapter 3: Methods 
3.1 Ethics statement 
The Canadian Memorial Chiropractic College and the Newfoundland Health Research 




 Fifteen individuals diagnosed with AxSpA were recruited from disease-specific interest 
groups and rheumatology practices in the Greater Toronto Area. All participants were required to 
be older than 18 years of age and have a confirmed diagnosis of AxSpA. Potential participants 
who were occupationally exposed to radiation as well as women who were or might be pregnant 
were excluded. 
 
3.3 Collection procedure 
 After completing the informed consent process, the participant was instrumented with 
accelerometers and landmarks were made for the tape measurements. The two tapes were 
instrumented beneath the accelerometers so that the accelerometers did not impede the tape 
measurement methods, which minimized the time taken between tape, accelerometer and 
radiographic measures (Figure 3). To synchronize the measures as much as possible, 
accelerometer data were simultaneously collected during each radiographic exposure via a thumb 
switch trigger initiated by the Registered Radiologic Technologist (RRT) as the exposure switch 
was engaged. Lateral and PA reference upright standing radiographs were taken first in a 
randomized order. Then, the following trials were collected in a randomized order: maximal 
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forward flexion (OST, MST, MMST), maximal right lateral flexion, maximal left lateral flexion 
[Lateral Spinal Flexion (LSF) test] and bilateral flexion (Domjan test). For these trials, the 
corresponding clinical tape measurements were taken first as the participant held the end range 
position immediately followed by the synchronized accelerometer data and radiographic 
exposure. The participant held each position for approximately six to seven seconds, while all 
three methods were measured. To minimize errors, all tape and accelerometer measures were 
taken by John Charles Snow (JCS). 
 
3.4 Instrumentation 
Prior to the commencement of the data collection, JCS palpated the lumbar spine region for 
purposes of landmarking anatomical reference points for the instrumentation of the tape 
measures and accelerometers.  
 
3.4.1 Tape measures 
With the subject in an upright standing position, JCS located the 12th thoracic vertebrae 
by palpating the inferior aspect of the last rib and tracing inwards to its articulation with the 12th 
thoracic vertebrae. Individual vertebral levels were counted by tracing down the spinous 
processes of the lumbar vertebrae until reaching the inferior endplate of the 5th lumbar vertebrae, 
which established the lumbosacral joint (LSJ). A horizontal reference line was marked with pen 
at the level of the LSJ. While a tape measure was help firmly to the skin, three more horizontal 
reference lines were drawn with the subject in upright standing: 10 cm above, 15 cm above, and 
5 cm below the reference line made at the LSJ. Two tape measures were affixed to the 
participant prior to collecting data: one that ran underneath the fixed accelerometer atop the 1st 
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lumbar vertebrae for the MMST measure and one that ran underneath the accelerometer fixed 
atop the sacral base for the OST and MST measures (Figure 3). 
 
Figure 3. Visual representation of two tape measures lying underneath the L1 and S1 accelerometers. 
 
3.4.2 Accelerometer measures 
 Two tri-axial accelerometers (ADXL335, Analog Devices, Norwood, MA, USA) were 
calibrated in relation to gravitational acceleration. JCS located the 12th thoracic vertebrae via 
surface palpation as described above. Tracing down one spinous process established the 1st 
lumbar vertebrae (L1) where a horizontal reference line was made with a pen. Using the 
previously established reference line at the level of the LSJ, JCS traced down one spinous 
process to establish the first sacral vertebrae (S1) where another horizontal reference line was 
marked. The subject was then instrumented with two accelerometers fixed atop the L1 and S1 
reference lines using double sided tape in the + y down orientation. Figure 4 illustrates a tri-axial 
accelerometer and the accelerometer encased in protective plastic in a +y down orientation. 
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Fabric tape (Soft Cloth Tape, 3M, St. Paul, MN, USA) was placed atop each accelerometer to 
ensure there was no sensor movement relative to the skin throughout range of motion trials.  
 
 
Figure 4. A. Tri-axial accelerometer. B. Tri-axial accelerometer encased in plastic in a +y down 
orientation as instrumented on the participant. 
 
3.4.3 Radiographic measures 
Radiographic technique factors were set based on the torso thickness measurement in 
both the sagittal and frontal planes for each participant. Subjects were fitted with thyroid and 
gonadal shielding to protect radiosensitive tissues from x-ray scatter.  
 
3.5 Data Collection 
3.5.1 Tape Measures 
Forward lumbar spine flexion range was assessed using the OST, MST and MMST. The 
OST was conducted using the two reference lines at the level of the LSJ and 10 cm above the 
LSJ as established during instrumentation. With the legs shoulder with apart, the participant was 
 31 
instructed to bend forward reaching their fingertips to the floor. The distance between the two 
reference lines was then measured at maximum forward flexion. The distance between the lines 
in forward flexion minus 10 cm (distance between lines at upright standing) indicated the OST 
measure to the nearest mm. 12 The MST was conducted using the two references lines that were 
drawn 5 cm below the LSJ and 10 cm above the LSJ as established during instrumentation. With 
the subject in the same maximally forward flexed posture as described for the OST measure, the 
distance between these two reference lines was measured. The distance between the lines in 
forward flexion minus 15 cm (distance between lines at upright standing) indicated the MST 
measure to the nearest mm. 12 The MMST was conducted using the two references lines that 
were drawn at the level of the LSJ and 15 cm above the LSJ as established during 
instrumentation. With the subject in the same maximally forward flexed posture as described for 
the OST measure, the distance between these two lines was measured. The distance between the 
lines in forward flexion minus 15 cm (distance between lines at upright standing) indicated the 
MMST measure to the nearest mm. 12 All three Schober’s variations are illustrated in Figure 1 on 
page 19. Lateral spine bending range was assessed using the lateral spinal flexion (LSF) test and 
Domjan test. The LSF test was conducted with the subject in a standing position with their feet 
shoulder with apart and hands at their sides. With their right hand on the lateral aspect of the leg, 
the distance between their right middle finger and the floor was measured in upright standing. 
The subject was then asked to maximally bend to the right, keeping the trunk in the frontal plane 
and maintaining feet in contact with the floor. The distance from the right middle finger and the 
floor was then measured at maximum lateral bend. The difference between the measures at 
upright standing and maximum lateral flexion was recorded to the nearest mm. This was then 
conducted on the left side of the body and as instructed by the ASAS guidelines, an average of 
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the two sides indicated the LSF measure. 59 The Domjan measure of bilateral spine bending was 
taken as the measurement (nearest mm) between two horizontal lines as marked on the 
participant’s right leg during right and then left side bending. Specifically, the first horizontal 
line was marked with a pen on the person’s skin at the point where the tip of right middle finger 
touched the lateral side of the leg at end range right lateral flexion. The second horizontal line 
was drawn during left lateral flexion where the tip of the right middle finger touched the right 
thigh. The distance between these two marks on the right leg indicated the total range of side 
flexion, as a combination of both sides. 60 Each measure was taken once, read out loud by JCS 
and recorded by a research assistant. Both lateral spinal mobility tests are illustrated in Figure 2 
on page 20. 
 
3.5.2 Radiographic Measures 
For all views, collimation was set superiorly to include the vertebral body of T12, 
inferiorly to include the vertebral body of S3. Two upright standing reference films were taken: 
posteroanterior (PA) lumbar and lateral lumbar. This was followed by three end range flexion 
films: lateral lumbar view of forward flexion, PA lumbar view of right lateral flexion and a PA 
lumbar view of left lateral flexion. All films were taken with the feet shoulder width apart. For 
each film, breathing instructions were given by the radiographic technologist such that the film 
was taken on suspended expiration in order to minimize superimposition of the diaphragm over 
the upper lumbar vertebral bodies. To control for the effect of arm position on lumbar spine 
angle, participants were instructed to have their arms crossed over their chest for all trials. 76 All 
films were taken with a diagnostic x-ray high voltage generator machine (HFQ-12050P, Toshiba, 
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Bennett X-ray Technologies Inc., Copiague, NY, USA) by an experienced (42 years of practice) 
RRT with a 36 by 43 cm film size using 400 speed screen digital cassettes. 
 
3.5.3 Accelerometer measures 
Two upright standing accelerometer measures were taken concurrently with the 
posteroanterior and lateral lumbar radiographs. This was followed by three measures taken in 
forward end range flexion, left lateral end range flexion and right lateral end range flexion.  
 
3.6 Data Processing 
3.6.1 Accelerometer measure 
For all accelerometer measurements, the RRT used an external trigger to time synch the 
radiographic exposure to the accelerometer measure. For all accelerometer data, an average value 
of the 1-1.5 seconds that the RRT held down the trigger was taken. From the calibration trials, 
conversion factors were calculated using voltage output from the accelerations in +1 g, -1 g and 
0 g (where g = -9.81m/s2) and the sensitivity of each axis (Equation 1). The arctan function was 
then applied to the accelerometer values to give the absolute inclination of both sensors 
respectively (Equations 2, 3). Relative lumbar spine angles were then calculated between the top 
and bottom sensor (Equation 4). In theory, this relative lumbar spine angle is analogous to the 
radiographic measure as calculated from the x-ray image (Figures 5, 6). For each trial, the 
difference in relative lumbar angle from upright standing to end range bending was used to 
calculate range of motion (ROM) in degrees. An average of left and right lateral bending was 
computed to indicate the accelerometer measure of lateral spine flexion range of motion. 
Accelerometer data were collected with a 16-bit analog-to-digital conversion board at a sample 
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rate of 32 Hz (NiDAQ, National Instruments, Austin, TX, USA) using custom written data 
acquisition software (Matlab version 2015b, The MathWorks Inc., Natick, MA, USA). 
 
 
Figure 5. The radiographic method of calculating the lumbar spine angle from a lateral projection 
radiograph film. 77 Horizontal lines are drawn parallel and through the superior endplate of L1 and the 
superior endplate of S1. Perpendicular lines are drawn from the two original lines and the large angle at 
their intersection is measured. Figure drawn by JC Snow. 
 
Figure 6. Method of calculating the lumbar spine angle from posteroanterior plain radiograph. 77 
Horizontal lines are drawn parallel and through the superior endplate of L1 and the superior endplate of 
S1. Perpendicular lines are drawn from the two original lines and the large angle at their intersection is 




Equation 1. Accelerometer calibration equation for an axis. Using the + Xup  calibration trial as an 










Equation 2. Calculating the absolute angle of an individual accelerometer. This gives an angle of rotation 












Equation 3. Calculating the absolute angle of an individual accelerometer. This gives an angle of rotation 













Equation 4. Calculation of the relative lumbar spine angle between the top (L1) and bottom (S1) 
accelerometers. 
θrel = θabs of top accel - θabs of bottom accel 
 
3.6.2 Radiographic measure 
Radiograph angles were calculated from the digital films by JCS using the Horos 
DICOM software (Horos v2.4.0, Pixmeo SARL, Geneva, Switzerland). All films were 
randomized and blinded prior to being measured. 
Lumbar angles of forward flexion were calculated from the lateral view radiographs 
according to the commonly used method presented in Figure 5. Specifically: a line was drawn 
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through and parallel to the superior endplate of the first lumbar segment and a second line was 
drawn through and parallel to the superior endplate of the first sacral vertebra. Perpendicular 
lines were drawn from both original lines and extrapolated. The large angle at their intersection 
was measured to give the relative lumbar angle. 77 The difference between the relative lumbar 
angles from upright standing to maximum flexion was then used to represent the forward 
bending range of motion (Equation 5). The range of lateral bending was measured from the PA 
radiographs as follows: a line was drawn through and parallel to the superior endplate of the first 
lumbar segment and a second line was drawn through and parallel to the superior endplate of the 
first sacral vertebra. Then, erected perpendicular lines were drawn at right angles to both original 
lines. The angle at which these lines intersect was then measured 77 (Figure 6). Range of motion 
in lateral bend was calculated bilaterally by the difference in relative lumbar angles from upright 
standing to end range lateral bend (Equation 6).  
 
Equation 5. Calculation of the Forward flexion range of motion (ROM) for radiographic measurements. 
Forward Flexion ROM (°) = θrelative of max forward flexion - θrelative of upright stand  
 
 
Equation 6. Calculation of lateral flexion range of motion (ROM) from upright standing to maximum 
lateral flexion posture. 
Lateral Flexion ROM (°) = θrelative of max lateral flexion - θrelative of upright stand 
 
 
3.7 Statistical analysis 
Corresponding measures of spine flexion motion from the tape measure and 
accelerometer were analyzed alongside the radiograph data using a scatterplot. Pearson’s 
correlation coefficients (r) were used to assess the correlation between both measurements 
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(clinical tape and accelerometer) with reference to the radiographic data. Interclass Correlations 
(ICC) were calculated to observe the level of agreement between the accelerometer and 
radiographic measures. A Bland-Altman analysis was completed to further test for the presence 
of proportional bias between the accelerometer and radiograph data. A Bland-Altman analysis 
could not be completed between the tape measure and radiographic data because they have 
different units of measurement. Statistical significance was taken at p < 0.05 and correlation 
coefficients at |r| > 0.20. To assess intra-rater reliability, JCS performed repeat measures of the 
radiographic angles from two sets of films: PA view upright standing and lateral view forward 
bending radiographs of all fifteen participants. These measures were taken at the same time of 
day on three consecutive days. Inter-rater reliability was assessed by comparing the measures 
made by a second trained rater to those originally made by JCS for the two sets of films as 
indicated above. Intraclass correlations were calculated to measure the inter- and intra-rater 
reliabilities of radiographic measures. Means and standard deviations were calculated for all 
measures. All statistics from this analysis were completed using SPSS software (SPSS Statistics 




Chapter 4: Results 
4.1 Participant Demographics 
Table 2 presents the demographic and anthropometric characteristics of the study population.  


























11.65 ± 9.35 
 
 
4.2  Forward Bending  
Table 3 presents correlation data for all forward bending spinal mobility tests. Figure 7 
presents a graphical summary of the results from the measurement tests in forward bending. 
Pearson’s correlations between OST, MST and MMST tape measurements to radiographic gold 
standard were very weak (r=0.195, p=0.243), weak (r=0.295, p=0.143), and moderately strong 
(r=0.414, p=0.063) (Figure 8) respectively. The accelerometer measure displayed a significant 
(p=0.010), moderate-strong correlation (r=0.590) (Figure 9), compared to the gold standard 
radiographic values. Interclass correlations between the accelerometer and radiographic 
measures indicated a fair level of agreement (ICC=0.583, p=0.009). A Bland-Altman analysis 
comparing the radiographic and accelerometer measures was conducted to test for the null 
hypothesis that there was no proportional bias between the two measures (Figure 10). A t-score 
of 0.717 and a significance level of p=0.486 was computed. This t-score was not significant and 
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therefore we accepted the null hypothesis indicating that there are no systematic differences 
between the accelerometer and the radiograph at a particular range of values.  
 
Table 3. Summary correlations for spinal mobility tests in forward bending. * indicates statistical 











OST vs. Radiograph 0.195 0.243 Very Weak 
MST vs. Radiograph 0.295 0.143 Weak 
MMST vs. Radiograph 0.414 0.063 Moderate 






Figure 7. Mean results (S.D.) for spinal mobility tests in forward bending. Radiograph and accelerometer 
angles are presented in degrees (º). Tape measurements are presented in millimetres (mm). 
 
Figure 8. A scatterplot presenting the change in radiographic L1-S1 angles (º) from upright standing to 
maximum forward bending (x-axis) compared to the Modified-Modified Schober’s Test (mm) scores for 

















































Δ L1-S1 (standing - max forward flexion) Radiograph (°)r=0.414, p=0.063
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Figure 9. A scatterplot presenting the change in radiographic L1-S1 angles (º) compared to the change in 
accelerometer L1-S1 angles (º) from upright standing to maximum forward bending (x-axis) for each 















































Δ L1-S1 (standing - max forward flexion) Radiograph (°)r=0.590, p=0.010
 42 
 
Figure 10. A Bland-Altman plot comparing the accelerometer and radiographic measures of forward 
bending. The Bland-Altman analysis indicated that there were no systematic differences between the two 
measures at a particular range of values. 
 
4.3 Lateral Bending  
Table 4 presents correlation data for all lateral bending spinal mobility tests. Figure 11 
presents a graphical summary of the results from the measurement tests in lateral bending. 
Measurements from the LSF test were reported as an average of left and right lateral ranges of 
motion. The LSF test had a significant (p=0.001), strong correlation (r=0.743) (Figure 12) 
compared to radiographic measures. The Domjan method of bilateral flexion also presented a 
significant (p=0.002), strong correlation (r=0.708) (Figure 13) to the radiographic gold standard 
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of spinal mobility measurement. The correlation between accelerometer and radiographic 
measure of lateral bending was found to be moderately strong (r=0.556, p=0.016) (Figure 14). 
Pearson’s correlation coefficients were also individually observed for right and left lateral 
bending measures. In comparing left lateral flexion measure to the radiographic measure, the 
tape measure was found to be moderately correlated (r=0.529, p=0.021), while the accelerometer 
had a weak correlation (r=0.303, p=0.136). In right lateral bending, the tape measure showed a 
strong correlation (r=0.727, p=0.001) while the accelerometer also had a strong correlation 
(r=0.670, p=0.003) to radiographic reference standard.  
 
Table 4. Summary correlations for spinal mobility tests in lateral bending. * indicates statistical 











LSF vs. Radiograph 0.743 0.001* Strong 
Domjan vs. Radiograph 0.708 0.002* Strong 




Figure 11. Mean results with standard deviations for spinal mobility tests in lateral bending. Radiograph 
and accelerometer angles were calculated as an average of left and right lateral bending and presented 
in degrees (º). The LSF test was calculated as an average of left and right lateral bending while the 
Domjan test was calculated as a sum of left and right lateral bending. Tape measurements are presented 
in centimetres (cm). 
 
Figure 12. A scatterplot presenting the LSF radiographic measure compared to the LSF tape measure. 
The radiographic ranges of motion were calculated as a change in radiographic L1-S1 angles (º) from 
upright standing to maximum lateral bend for both sides. Both measures are presented as an average of 
left and right lateral bending ranges of motion. These two measures had a strong Pearson’s correlation 








































Figure 13. A scatterplot presenting the LSF radiographic measure compared to the Domjan tape 
measure. The radiographic ranges of motion were calculated as a change in radiographic L1-S1 angles 
(º) from upright standing to maximum lateral bend for both sides. The radiographic measure is presented 
as an average of left and right lateral bending ranges of motion. These two measures had a strong 




























LSF radiographic measure (°)r=0.708, p=0.002
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Figure 14. A scatterplot presenting the LSF radiographic measure compared to the LSF accelerometer 
measure. Ranges of motion were calculated as a change in L1-S1 angles (º) from upright standing to 
maximum lateral bend (z-axis) for both sides. Both measures are presented as an average of left and right 
lateral bending ranges of motion. These two measures had a moderate Pearson’s correlation coefficient 
of r=0.556, p=0.016. 
 
4.4 Intra-rater/ Inter-rater Agreement of Radiographic Measure 
There was an excellent level of agreement (ICC=0.966, p<0.000) observed when testing the 
inter-rater reliability between JCS and a second trained rater. Intra-rater reliability also presented 






























LSF radiographic measure (°)r=0.556, p=0.016
 47 
Chapter 5: Discussion 
In this chapter, the results of the thesis will be further explored in the context of the 
primary research question. The strengths and limitations of the study will be considered and 
future directions for this work will be identified. The overall goal of this thesis was to investigate 
an alternative method of spinal mobility measurement in forward and lateral bending using tri-
axial accelerometers. Specifically, to determine the extent to which the accelerometers compare 
to traditional tape measurement methods in terms of criterion-concurrent validity using the 
radiographic measure as a reference standard. Previous literature has suggested that the current 
clinically used tape measurements in sagittal bending are not a valid measure of spine motion 
12,53,56,58. Therefore, it was hypothesized that the range of spine motion calculated from the tri-
axial accelerometers would be a more valid measure of spinal mobility than the tape 
measurement methods. The monitoring of spinal mobility limitations in AxSpA patients provides 
a snapshot of disease progression and treatment responses. Thus, by exploring a potentially 
improved method of spinal mobility measurement it may be possible to improve the ability to 
identify symptoms and monitor its progression; ultimately improving the clinical management 
and quality of life of this patient population. 
 
5.1 Forward Bending 
Accelerometry was superior to clinical tape measure in measurement of forward spine 
flexion. We confirm that the use of tri-axial accelerometers correlate stronger with the 
radiographic measure in forward flexion, thereby suggesting that it is a better alternative to the 
current Schober’s test measures. The accelerometer method used in our study yielded a Pearson’s 
correlation coefficient of r=0.590, with a p-value of 0.010 in forward bending mobility 
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measurement. This significant, yet moderately strong correlation reflects spinal mobility better 
than its tape measurement counterpart, while still providing an inexpensive, easy to apply and 
potentially feasible method of measuring spine motion. In this stronger measure of spinal 
mobility, a relative angular measurement is extracted from two individual accelerometers, which 
is not dependant on the elastic properties of the skin. The Schober’s tape measure variations 
produce measures that rely on the stretching of the skin when evaluating forward spinal flexion 
mobility. Research has reported large systematic differences at end ranges of spinal flexion when 
using current clinical tape measures. 58At larger ranges of flexion the skin begins to slide across 
the underlying tissues rather than continuing to stretch, thereby causing disproportional changes 
to the Schober’s measurement. 58 This may explain the stronger correlations to radiographic gold 
standard in the accelerometer measure compared to the three Schober’s tests. At large ranges of 
motion where the skin stretching transitions to skin sliding across the tissues beneath the 
accelerometers, this may introduce a minor measurement bias. However, the results of the Bland-
Altman analysis confirmed that there was no proportional bias between the radiograph and the 
accelerometer measures so we can be confident that this risk of bias is small. In theory, the 
accelerometers will still capture an angle that is methodologically analogous to the radiographic 
measure as presented in Figure 5. Consequently, accelerometers may present an increased benefit 
in assessing patients in the early stages of the disease, where larger spinal ranges of motions are 
more likely and tape measures are likely more susceptible to disproportional changes. Although 
the accelerometer correlated stronger to the radiographic measure than the tape measures in 
forward flexion, we could assume that this difference in correlational strength between measures 
would be more pronounced in a sample with a smaller disease duration and in turn, greater spinal 
ranges of motion. Upon completing spinal mobility assessment of this patient sample, it is 
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evident that their range of motion was limited by their disease activity. An Original Schober’s 
test indicating a change of less than 50 mm can be interpreted as a positive test for spinal 
mobility limitations. 11 In our sample of 15 AxSpA patients the mean OST score was 22.97 mm  
± 15.09 mm while the average duration since diagnosis in this sample was 11.65 yr ± 9.35 yr.  In 
contrast, the 50 patient cohort from the Rezvani study that evaluated forward bending tape 
measures had a mean OST score of 40.7 mm ± 18.8 mm with a mean time since diagnosis of 
3.90 yr ± 4.44 yr. Relatively speaking, our 15 patient sample had a much longer duration since 
diagnosis and, accordingly, their spinal mobility in forward bending was far more limited. We 
could not accurately approximate the time since initial presentation of symptoms associated with 
AxSpA, therefore, this time since diagnosis does not account for diagnosis delay between onset 
of symptoms and clinical diagnosis. Since previous research in spine motion measurement has 
proven that the use of accelerometry is a reliable technique in the repeated measurement of 
forward bending lumbar spine movement in a healthy population 65, we can be confident that 
accelerometers are a good measure of spine motion. It may just be that in our current population, 
the decreased range of motion limited the difference of correlation strength between 
accelerometer and tape measure. Specifically, if our sample had included an early diagnostic 
group with a larger range of motion, we could hypothesize that lower correlations would be 
observed in the tape measure, further favoring the accelerometer measure of forward bending 
spinal mobility. The results from our investigation suggest that the tri-axial accelerometers have 
potential to improve the clinical measurement of forward bending spinal mobility in AxSpA and 
our findings should be expanded on through future work within this clinical population.  
We confirm that tape measure methods have overall poor concordance with gold standard 
radiography when assessing forward flexion. The results of the forward bending trials in this 
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study, using the OST, MST and MMST are in accordance with the methodologically similar 
study from Rezvani et al. (2002), which was considered to be high quality according to the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS) assessment tool. Their study 
established a weak correlation to the radiographic measurement for the OST (r=0.363, p=0.018) 
and MST (r=0.333, p=0.018) measures in patients with Ankylosing Spondylitis. Similar weak 
correlations for OST (r=0.195, p=0.243) and MST (r=0.295, p=0.143) were found in our 
analysis. We are unable to compare our results for the MMST; as the Rezvani team did not report 
this measure as they concluded that the measure did not reflect spine mobility. There is very 
limited evidence regarding the criterion-concurrent validity of MMST with reference to the 
radiographic gold standard of spinal mobility measurement in AxSpA patients. The MMST was 
originally designed for spinal mobility measurement in patients with AS, but has largely been 
used to measure ROM in the general population. This has limited the conclusions regarding the 
validity of this measure in the originally intended AxSpA population, who typically have a 
smaller lumbar spine ROM. 19 The one other study that has reported results regarding the validity 
of MMST compared to radiographic gold standard was completed in a cohort of LBP patients, 
rather than in the AxSpA population. 53 Although this study reported Pearson’s correlation 
coefficient of 0.67, it was not regarded as high quality (QUADAS) in the systematic review by 
Littlewood and May 78 because the observers were not blinded from the  MMST results when 
interpreting the radiographic measures. In our study, all films were duplicated, blinded, and 
graded in a randomized order using the Horos DICOM Software. The LBP cohort had a mean 
MMST measure of 63.00 mm ± 14.00 mm where as our AxSpA had a mean MMST measure of 
31.87 mm ± 17.47 mm. This contrasting result illustrates the evident mobility differences 
between a LBP and an AxSpA cohort, further weakening the generalizability of their findings to 
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the intended population.  In our investigation in AxSpA patients, MMST held the largest 
correlation of the three forward bending tape measures to the radiographic gold standard. MMST 
moderately correlated (r=0.414) to the radiographic measure and was not statistically significant 
(p=0.063). As mentioned above, all three Schober’s tests rely on the stretching of the skin to 
produce a measure representative of forward bending spinal mobility. Research has shown the 
disproportional changes in tape measure tests at larger ranges of forward bending. 58Additionally, 
a study looking at structural deformation of skin in response to spine posture changes found that 
individuals with greater subcutaneous fat/fascia were associated with greater skin structural 
deformation in forward flexion. 79 In other words, skin stretching is not proportional to the true 
spinal range of motion and consequently, tape measures of forward spinal mobility are 
confounded by the body type of the individual. In summary, none of the forward bending clinical 
tape measures used in this study performed adequately. This warrants the need of further 
research into the use of alternative methods of sagittal plane spinal mobility measurement, such 




5.2 Lateral Bending 
 The ASAS recommends the use of the BASMI as a way to assess spinal mobility in 
AxSpA. 59 This is a compound index that combines five clinical measurements that reflect axial 
mobility. For example, the Modified Schober’s test is used to assess forward spinal bending 
ROM, while the Tragus-to-Wall test measures cervical and thoracic spine mobility. The Lateral 
Spinal Flexion test, as evaluated in this study, is included in this index as an assessment of lateral 
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mobility of the spine. It is a common misconception that these five individual measures are in 
fact valid measures of spinal mobility in AxSpA patients. Although the individual tests that make 
up the BASMI have been shown to have construct validity in predicting disease factors such as 
structural damage 34,80, there is very limited evidence for the criterion-concurrent validity of 
these individual tests and an accepted reference standard. 13 Without confirmed evidence of 
concurrent validity, it cannot be assumed that the LSF test is a truly adequate measure of its 
intended use, which is to provide a measure of lateral spinal range of motion. For the LSF test 
specifically, this was the first study to evaluate the criterion-concurrent validity of the test with 
reference to the widely accepted radiographic gold standard. There has been no study that has 
validated the commonly used Lateral Spinal Flexion tape measurement test with comparison to 
the radiographic gold standard measure of spinal mobility. A study completed by Moll et al. 
found a correlation coefficient of r=0.79 when compared to radiographic measures for a 
methodologically different lateral tape measurement test, however, the results came from pooled 
data from a sample of AS patients (n=18) and a larger sample of healthy controls (n=36). To our 
knowledge, our study is the first to investigate the criterion-concurrent validity of the ASAS 
recommended clinical LSF tape measure.  
Tape measure tests have strong concordance with radiographic measurement in lateral 
spine flexion. Upon comparing both the LSF test and the accelerometer method of measuring 
lateral spine flexion range of motion, the tape measure had a strong correlation (r=0.743, 
p=0.001) to radiographic measures while the accelerometer had a moderate strength correlation 
coefficient (r=0.556, p=0.016). It can therefore be suggested that the LSF tape measure is a valid 
measure of lateral spinal flexion in the intended AxSpA population. The methodology of the LSF 
test does not require landmarking of anatomical reference points such as surface palpation and 
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pen marking that is required for the placement of accelerometers. This minimization of 
measurement bias may explain the differential benefit of the tape measure versus the 
accelerometer in measuring lateral spine bending range of motion. It is important to note that the 
LSF measure is taken from an average of both sides. When collecting experimental data, 
repeating a measure and taking an average decreases the variability of the measure, thus 
increasing the reliability and accuracy. This may explain the strong correlations occurring in this 
measure. This raises the question that if the time was taken to collect multiple forward flexion 
measures and average them, would they present stronger correlations? The following conclusions 
are important from a clinical assessment stand point as the values were the result of a clinically 
used test, which averages both left and right flexion ranges to represent lateral spine mobility as 
a whole. From a basic science standpoint, comparing the measures of left and right side bending 
for the tape and accelerometer measures could be a more direct representation of the measure’s 
validity. In both individual side-bending measures, the tape measure (left: r=0.529, p=0.021; 
right: r=0.727, p=0.001) had a stronger correlation to the radiographic gold standard than the 
accelerometer measure (left: r=0.303, p=0.136; right: r=0.670, p=0.003). These findings further 
suggest that the tape measurements are a more valid measure of spinal mobility when measuring 
lateral ranges of motion. The tape and accelerometer measures in right lateral bending both 
correlate strongly to the radiographic measure. This finding may indicate that with further 
research, the accelerometer may prove to be a valid measure of lateral spinal mobility but does 
not warrant the use of this method in place of the tape measure at this time. However, we are 
interested in further investigating the validity of both the accelerometer and the tape 
measurement of lateral spinal range of motion in AxSpA. There was a difference in the strength 
of correlations between left and right side bending for both measurements methods. The 
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literature presents no evidence for predominant disease related spinal mobility restrictions in left 
lateral bending versus right lateral bending in this patient population. There was no statistically 
significant difference (p=0.849) between left and right lateral bending radiographic measures. 
Therefore, the difference in correlation strength between sides in this population cannot be 
explained by a larger ROM in one side versus the other. This discrepancy of correlations 
between left and right sides raises questions and further justifies the designing of a study that will 
expand on this sample to investigate the validity of both tape and accelerometers in measuring 
spinal mobility in this population. The Domjan tape measure of bilateral spinal bending 
correlated strongly (r=0.708, p=0.002) to the radiographic measure proving to also out-perform 
the lateral flexion accelerometer measure. Although this method had a slightly smaller 
correlation compared to the LSF test (r=0.743, p=0.001), this relatively new test can be 
conducted and analyzed quicker in a clinical setting. This test requires the participant to perform 
two postural movements (maximum lateral bending on both sides) and requires the clinician to 
report only one measure between two markings on the patient’s leg. From a conducting 
perspective, this is quick and easy as opposed to the four measures that are taken for the LSF 
test, which requires subtraction and averaging of multiple measures to arrive at a test result. It is 
also important to note that this test does not average multiple measures as the LSF test does. As 
we know, averaging multiple measure decreases the variability of a measure, thereby improving 
accuracy and reliability. This suggests that the results of the Domjan measure may be stronger in 
nature than the averaged measure presented by the LSF test. This test is ultimately quick and 
easily implemented in a clinical setting. Our findings confirm that tape measure, whether using 
the LSF or Domjan technique, is valid for assessing lateral spine flexion. 
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5.3 Strengths and Limitations 
The Domjan and LSF tape measurement tests are currently being used clinically with the 
assumption that they are a true valid measure of spinal range of motion. This was the first 
investigation to evaluate the criterion-concurrent validity of the LSF and Domjan clinical tape 
measurements compared to the radiographic gold standard of spine motion measurement. This is 
the most objective way of assessing the true validity of a clinical measurement. 81 We confirmed 
that both the Domjan and LSF tests were valid measures of lateral spinal mobility. This study 
was also the first to examine the criterion-concurrent validity of tri-axial accelerometers in the 
measurement of spinal mobility in the very relevant AxSpA patient population. The findings of 
this study highlight the potential for tri-axial accelerometers in measuring spine motion, 
warranting further research into the application of these cheap, easily implementable sensors.  
There were also several limitations to this study. Although we used a multitude of recruitment 
outlets including the Canadian Spondylitis Association, clinicians from the Canadian Memorial 
Chiropractic College and disease specific interest groups in the Greater Toronto Area, we did not 
reach our desired sample size of thirty AxSpA patients. We therefore used convenience sampling 
to reach a small sample of fifteen patients, which was ultimately a limitation to the power of this 
study. The data for this study could not be collected at Eastern Health in St. John’s, 
Newfoundland due to barriers in accessing radiographic equipment for research purposes. 
Evaluating the criterion-concurrent validity of these two methods against the widely accepted 
radiographic gold standard of spinal mobility measurement required JCS to travel to North York, 
Ontario to gain access to the radiographic equipment at the Canadian Memorial Chiropractic 
College. Another limitation, which affected the sample size, was the expenses associated with 
this imaging study. The budget for this research could not accommodate for the wages of the 
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RRT, as well as living expenses in Toronto for longer than three months. Consequently, data 
collection was concluded after three months, where JCS returned to NL to continue analyzing the 
data from fifteen AxSpA patients. It was originally assumed that three months would be 
sufficient to collect the desired sample size, however, recruitment barriers became an unforeseen 
limitation. Recruiting from a patient population can pose problems, especially when participation 
involves commuting to the collection site, as it did in this study. The AxSpA population typically 
deals with inflammatory ‘flare ups’, which restricted two potential participants from 
participating. Another limitation to this study was that our convenience sample yielded only 
AxSpA patients from the radiographic/AS subgroup. This may be due to our inclusion criteria 
requiring a confirmed AxSpA diagnosis from a rheumatologist. Without definitive radiographic 
evidence, the diagnosis of non-radiographic AxSpA patients becomes increasingly subjective 
and can cause patients to be misdiagnosed or undiagnosed. 44 Because of this, many non-
radiographic patients may not even know they have AxSpA. This may explain the absence of 
non-radiographic cases in this study. This would reduce the generalizability of our results to the 
non-radiographic subgroup. To overcome this, our future work will not only focus on the earlier 
stage and non-radiographic cohort, but also prepare for a longer study period to ensure we reach 
a desired sample size.  
 Another limitation inherent to landmarking by surface palpation is the potential for 
measurement error caused by misplacement of the accelerometers and tape measures. To 
mitigate this risk, palpation and instrumentation of accelerometers and tape measures was 
completed by the same trained investigator for all participants. In this study we were able to 
confirm the actual location of accelerometers with respect to the vertebral landmarks on the 
radiographs. The bottom accelerometer was consistently placed over the sacrum and the top 
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accelerometer was never off by more than one vertebral level. Since the L1/L2 intervertebral disc 
angle only accounts for a small proportion of the lumbar lordosis angle, we are confident that 
errors in placement would contribute minimally to errors in the accelerometer measure. The 
placement of the tape measures could not be confirmed via radiograph because the vinyl material 
of the tape measure is not detected on a radiographic image.  
  
5.4 Future Direction 
The findings from this study gave light to a method of assessing spinal mobility in the 
AxSpA population using tri-axial accelerometers. This method presented more criterion-
concurrent validity than the three variations of Schober’s tape measures in forward bending 
measures. Although this may not warrant a change of practice at this stage, it does justify a 
follow up study that validates our findings in a larger sample set. Establishing which method of 
spinal mobility measurement is superior is imperative to the monitoring of this susceptible 
disease cohort.   
The future direction of this research also pertains to the further development of the tri-
axial accelerometers used in this investigation. The current accelerometers are wired and involve 
an instrumentation protocol that takes 4-5 minutes. This is not clinically feasible from both a 
utilization and a time perspective. Future work needs to be done to develop these sensors into a 
wireless, more user-friendly device that can be set-up in a simple and timely manner by a 
primary healthcare provider. Once these accelerometers are developed into a more feasible 
method of measurement, a series of studies should be done to expand upon the applications of 
these sensors. 
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As mentioned previously, the accelerometer measure has great potential for increased 
benefit in assessing early stage AxSpA patients with greater spinal mobility. Designing a study 
that evaluates the criterion-concurrent validity of these spinal mobility measures in individuals 
with a disease duration of less than two years can offer evidence as to whether accelerometers 
are a significantly more valid assessment tool at early stages of this disease.  
Research has investigated the use of clinical tape measures as a way of monitoring 
disease activity, both in patient follow up and to measure treatment response in clinical trials. 
68,82 Going forward, to enhance the applications of accelerometry in AxSpA, studies should 
assess the accelerometer’s responsiveness to change in pre- and post-biologic therapy. This will 
quantify the ability of these sensors in detecting clinically important changes over time, 
providing additional insight regarding the reliability and construct validity of this measurement 
tool.  
LBP is often characterized as being mechanical or inflammatory in nature, although there 
have been very limited attempts to distinguish between these groups based on clinical symptoms. 
Back pain accompanied with stiffness that worsens with immobility is often associated with 
inflammatory LBP. 15 Future work should involve evaluating spinal mobility using both tape 
measures and accelerometers in patients who report LBP to see if they can be used to 
differentiate between mechanical and inflammatory LBP. If these measures of spinal mobility 
can identify mobility changes in clinical follow-up, this can influence a physicians’ decision 
when attempting to distinguish the underlying cause of the back pain. This will then not only 
help provide basis for appropriate clinical management going forward, but also recognize 
inflammatory LBP as potential early stage spondyloarthritis allowing for earlier screening in 
suspected cases.  
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5.5 Impact of work  
This study was the first to investigate the criterion-concurrent validity of tri-axial 
accelerometers for measuring spinal mobility in the very relevant AxSpA population. This 
stronger measure of forward bending spinal mobility presents novel insight into developing 
improved non-invasive clinical assessment tools. The accelerometers used in this study are 
lightweight, inexpensive and an easily implementable method of measurement. With future 
studies validating the findings from this sample, there holds potential for important applications 
in the field of telemedicine, where they could be used at the primary care level as a method of 
disease monitoring. In a society where a fair portion of the population lives rurally, it is not 
always feasible for patients to commute into an urban area for their assessment. With a more 
objective, valid, and easily implementable assessment tool for measuring spinal mobility, 
barriers to patient accessibility can be mitigated by incorporating this improved method of 
measurement into local primary care clinics.  
 Our study was also the first to investigate the criterion-concurrent validity of the ASAS 
recommended clinical LSF tape measure as well as the more recent Domjan measurement of 
bilateral spinal mobility. The correlations that were found for both lateral spinal mobility 
measures with reference to the radiographic measure suggest that these are valid measurement 
methods and can continue to be used in clinical follow up. The findings discussed in this thesis 
will direct further research into the measurement tools that are being used clinically. This work 
has advanced the knowledge surrounding the clinical application of both tri-axial accelerometers 
and clinical tape measures in measuring spinal mobility, whilst warranting further development 
in tri-axial accelerometer technology. 
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Conclusion 
The variability across the literature regarding the criterion concurrent validity of tape 
measurements of sagittal lumbar spine flexion has raised many questions, although seemingly 
few solutions. Results from this study suggest that with further development, the accelerometer 
could be a clinically useful tool to assess forward flexion spinal mobility in the AxSpA 
population. For patients who have been previously diagnosed, this method of monitoring the 
spinal mobility limitations inherent to this disease can give a more accurate snapshot of the 
progressions of spinal involvement. With a more valid assessment tool, clinicians can have 
greater certainty when evaluating an individual’s response to treatment, thereby optimizing and 
improving clinical management. The criterion-concurrent validation of the Domjan and Lateral 
Spinal Flexion tape measurements provides novel and clinically relevant insight into the 
monitoring of lateral spine mobility limitations. Our results for the three variations of the 
Schober’s tests were in accordance with the inconclusive evidence for the validity of these 
measures. In conclusion, accelerometers have great potential to be developed into a clinically 
useful measurement tool, but only in terms of forward bending ranges of motion. The stronger 
correlations from the two lateral tape measurements suggest that the appropriate assessment tool 
is dependent on which range of motion is being assessed. In AxSpA, spinal mobility correlates 
strongly with disease duration, function and general health, 33,34 and is a core domain in 
monitoring disease activity. Clinicians often use spinal mobility measures as a way to see how 
well a patient is responding to therapies. 11 For example, if a patient’s spinal mobility is found to 
be decreasing upon follow-up assessment, this warrants the consideration of alternative 
therapies. Disease outcome is therefore reliant on the validity of spinal mobility assessment 
tools. Finding from this study indicate the potential for further improvements to the clinical 
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assessment of mobility in AxSpA. Developing up-to-date clinical guidelines is critical to disease 
management and this study has paved the way for future work in designing improved guidelines 
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 Appendix A. Accelerometer Calibration protocol 
To calibrate the accelerometer against gravity: 
1.  The accelerometer is attached to a square calibration block using double sided tape such that 
the sensor is parallel to the edge of the block. 
2. Six trials are collected flipping and rotating the block on a level surface such that data is 
recorded for +1g, -1g and 0g for each of the three axes. This will give a voltage output from the 
accelerations that is then used to calculate conversion factors. 
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Appendix B. Original Schober’s Test protocol 
This test is used to assess lumbar spine forward flexion mobility as follows: 
1. A horizontal mark is made at the level of the lumbosacral joint (LSJ) found via surface 
palpation. A second mark is made 10 cm above the original mark (measured with a clinical tape 
measure). 
2. The patient is instructed to maximally flex forward without bending their knees, at which time 
the examiner measures the distance between the two marks using the clinical tape measure. 




Appendix C. Modified Schober’s Test protocol 
This test is used to assess lumbar spine forward flexion mobility as follows: 
1. A horizontal mark is made 5cm below the level of the lumbosacral joint (LSJ), which is found 
via surface palpation. A second mark is made 10 cm above the LSJ (measured with a clinical 
tape measure). 
2. The patient is instructed to maximally flex forward without bending their knees, at which time 
the examiner measures the distance between the two marks using the clinical tape measure. 
3. 15 cm is deducted from this measured distance to give the Modified Schober’s Test value to 





Appendix D. Modified-Modified Schober’s Test protocol 
This test is used to assess lumbar spine forward flexion mobility as follows: 
1. A horizontal mark is made at the level of the lumbosacral joint (LSJ) found via surface 
palpation. A second mark is made 15 cm above the original mark (measured with a clinical tape 
measure). 
2. The patient is instructed to maximally flex forward without bending their knees, at which time 
the examiner measures the distance between the two marks using the clinical tape measure. 
3. 15 cm is deducted from this measured distance to give the Modified-Modified Schober’s Test 
value to the nearest millimetre. 
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Appendix E. Lateral Spinal Flexion Test protocol 
This test is used to assess lateral spine flexion mobility as follows: 
1. With the patient’s heels and back up against a wall and arms by their side, measure and record 
the distance between the middle fingertip and the floor. 
2. The patient is instructed to maximally flex laterally without trunk rotation. Measure distance 
from fingertip to the floor on the same side as previously measured. Record the difference 
between these two measures 
3. Repeat this on the opposite side and the average of the two sides is recorded as the Lateral 
Spinal Flexion Test value to the nearest millimetre. 
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Appendix F. Domjan Test protocol 
This test is used to assess lateral spine flexion mobility as follows: 
1. With the patient’s heels and back up against a wall and arms by their side, a horizontal mark is 
drawn on the participant leg at the level of the ipsilateral third finger at end range right lateral 
flexion. 
2. Mark another line at the level of the same finger on the same leg in end range left lateral 
flexion. 
3. Measure the distance between these two marks with a clinical tape measure to indicate the 
Domjan Test value to the nearest millimetre. 
 
